PRIVIA HEALTH GROUP INC (PRVA)
US74276R1023 - Common Stock
Overall PRVA gets a fundamental rating of 5 out of 10. We evaluated PRVA against 116 industry peers in the Health Care Providers & Services industry. PRVA has an excellent financial health rating, but there are some minor concerns on its profitability. While showing a medium growth rate, PRVA is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year PRVA was profitable.
In the past year PRVA had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: PRVA reported negative net income in multiple years.
PRVA had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of 1.81%, PRVA is doing good in the industry, outperforming 66.09% of the companies in the same industry.
PRVA has a better Return On Equity (3.25%) than 66.96% of its industry peers.
PRVA's Return On Invested Capital of 1.70% is in line compared to the rest of the industry. PRVA outperforms 48.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.81% | ||
| ROE | 3.25% | ||
| ROIC | 1.7% |
ROA(3y)-8.73%
ROA(5y)-2.74%
ROE(3y)-13.9%
ROE(5y)-2.6%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PRVA's Profit Margin of 1.11% is fine compared to the rest of the industry. PRVA outperforms 63.48% of its industry peers.
In the last couple of years the Profit Margin of PRVA has declined.
PRVA has a Operating Margin (0.87%) which is in line with its industry peers.
In the last couple of years the Operating Margin of PRVA has grown nicely.
PRVA's Gross Margin of 9.66% is on the low side compared to the rest of the industry. PRVA is outperformed by 79.13% of its industry peers.
In the last couple of years the Gross Margin of PRVA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.87% | ||
| PM (TTM) | 1.11% | ||
| GM | 9.66% |
OM growth 3Y-26.28%
OM growth 5Y30.07%
PM growth 3Y-28.56%
PM growth 5YN/A
GM growth 3Y-1.22%
GM growth 5Y2.55%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PRVA is destroying value.
PRVA has more shares outstanding than it did 1 year ago.
PRVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 4.52 indicates that PRVA is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.52, PRVA belongs to the top of the industry, outperforming 85.22% of the companies in the same industry.
PRVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.52 |
ROIC/WACC0.19
WACC9.19%
2.3 Liquidity
PRVA has a Current Ratio of 1.80. This is a normal value and indicates that PRVA is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of PRVA (1.80) is better than 67.83% of its industry peers.
PRVA has a Quick Ratio of 1.80. This is a normal value and indicates that PRVA is financially healthy and should not expect problems in meeting its short term obligations.
PRVA has a better Quick ratio (1.80) than 71.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
The earnings per share for PRVA have decreased strongly by -57.14% in the last year.
The earnings per share for PRVA have been decreasing by -14.87% on average. This is quite bad
The Revenue has grown by 18.03% in the past year. This is quite good.
Measured over the past years, PRVA shows a very strong growth in Revenue. The Revenue has been growing by 20.31% on average per year.
EPS 1Y (TTM)-57.14%
EPS 3Y-14.87%
EPS 5YN/A
EPS Q2Q%-66.67%
Revenue 1Y (TTM)18.03%
Revenue growth 3Y26.59%
Revenue growth 5Y20.31%
Sales Q2Q%7.41%
3.2 Future
PRVA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.79% yearly.
Based on estimates for the next years, PRVA will show a small growth in Revenue. The Revenue will grow by 0.05% on average per year.
EPS Next Y2%
EPS Next 2Y25.84%
EPS Next 3Y23.79%
EPS Next 5YN/A
Revenue Next Year1.78%
Revenue Next 2Y7.01%
Revenue Next 3Y9.68%
Revenue Next 5Y0.05%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
PRVA is valuated quite expensively with a Price/Earnings ratio of 115.80.
PRVA's Price/Earnings is on the same level as the industry average.
When comparing the Price/Earnings ratio of PRVA to the average of the S&P500 Index (28.05), we can say PRVA is valued expensively.
A Price/Forward Earnings ratio of 57.73 indicates a quite expensive valuation of PRVA.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PRVA is on the same level as its industry peers.
The average S&P500 Price/Forward Earnings ratio is at 20.07. PRVA is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 115.8 | ||
| Fwd PE | 57.73 |
4.2 Price Multiples
PRVA's Enterprise Value to EBITDA is on the same level as the industry average.
Based on the Price/Free Cash Flow ratio, PRVA is valued a bit cheaper than the industry average as 66.09% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 34.02 | ||
| EV/EBITDA | 78.52 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PRVA does not grow enough to justify the current Price/Earnings ratio.
PRVA's earnings are expected to grow with 23.79% in the coming years. This may justify a more expensive valuation.
PEG (NY)57.9
PEG (5Y)N/A
EPS Next 2Y25.84%
EPS Next 3Y23.79%
5. Dividend
5.1 Amount
No dividends for PRVA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PRIVIA HEALTH GROUP INC
NASDAQ:PRVA (5/31/2024, 7:01:02 PM)
After market: 17.37 0 (0%)17.37
+0.11 (+0.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.07B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 115.8 | ||
| Fwd PE | 57.73 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)57.9
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.81% | ||
| ROE | 3.25% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 0.87% | ||
| PM (TTM) | 1.11% | ||
| GM | 9.66% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-57.14%
EPS 3Y-14.87%
EPS 5Y
EPS Q2Q%
EPS Next Y2%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)18.03%
Revenue growth 3Y26.59%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y